Refine by
Disease Process Articles & Analysis
33 news found
As the field of genomics continues to evolve, long non-coding RNAs (lncRNAs) have emerged as a fascinating frontier, offering unprecedented insights into the complex regulatory mechanisms underlying biological processes and disease states. CD Genomics, a leading provider of high-throughput sequencing services, is at the forefront of this exciting development, empowering researchers to unlock the ...
CD Genomics, a trailblazing genomics and bioinformatics services provider, is delighted to announce the launch of the Long Amplicon Analysis (LAA) service, a mature genomic research method that promises to revolutionize the field. With LAA, scientists can now explore intricate genomic landscapes, facilitating groundbreaking discoveries and advancements in various branches of genomics. Long ...
Cellworks Group Inc. a leader in Precision Drug Development and Personalized Therapy Biosimulation, today announced results from a study that examined how Differentiation Scoring (DS) derived from key myeloid biomarkers in individual Myelodysplastic Syndrome (MDS) patients using the Cellworks Platform and Computational Biology Model (CBM) can predict response to Hypomethylating Agents (HMA). In ...
Cellworks Group Inc. a leader in Precision Drug Development and Personalized Therapy Biosimulation, today announced results from a Cellworks biosimulation pilot study, which examined the impact of mismatch repair deficiency (MRD) on survival of temozolomide (TMZ)-treated patients with MGMT methylated (m-MGMT) glioblastoma (GBM). The biosimulation study validated that TMZ does not trigger ...
The field of protein DNA/RNA interactions is an expanding area of research. These interactions affect fundamental processes and as a result, relevant protein DNA/RNA processing complexes and their associated mechanisms provide interesting therapeutic targets to researchers. However, due to the complex and often delicate nature of these systems, traditionally researchers haven’t had ...
Cellworks Group, Inc., a world leader in Genomic Biosimulation Services for Precision Pharma and Personalized Oncology, today announced it has won The Challengers Innovative Business of the Year Award. Dell Technologies, in collaboration with Moneycontrol, CNBC TV-18, Intel, and Ernst and Young, established The Challengers Awards to recognize the agility and innovation displayed by IT innovators. ...
Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-203A study, which demonstrate that the Cellworks Biosimulation Platform and SingulaTM Therapy Response Index (TRI) was strongly predictive of Overall Survival (OS) for non-small cell lung cancer (NSCLC) patients and can provide ...
Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-024-04 study, which demonstrate that the Cellworks SingulaTM Therapy Response Index (TRI) was strongly predictive of Overall Survival (OS) and Progression-Free Survival (PFS) for newly diagnosed Glioblastoma Multiforme (GBM) patients. In ...
Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-004 study, which demonstrate that the Cellworks SingulaTM Therapy Response Index (TRI) is highly predictive of Overall Survival (OS), Disease-Free Survival (DFS) and Mandard-tumor regression grade (TRG) for gastroesophageal adenocarcinoma ...
Data from the Phase 1 dose-escalation portion of the Phase 1/2 EXACT study demonstrate XC001 was well-tolerated at all dose levels tested; highest dose level evaluated selected for ongoing Phase 2 portion of the study – Preliminary efficacy data highlight XC001 potential for patients with refractory angina with no other treatment options – Treatment strategy is to use local ...
Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that its prostate cancer test, IsoPSA, has been added to the National Comprehensive Cancer Network (NCCN) Guidelines for Prostate Cancer Early Detection (version 1.2022). The NCCN panel now recommends the use of IsoPSA as an option to ...
Debiopharm Innovation Fund (www.debiopharm.com/digital-health/), the strategic digital health investment arm of Debiopharm, announced their co-investment in Fosanis, a Berlin-based digital health company developing Mika, Germany’s first prescription DTx across all oncology indications. The series A funding round of more than 10 million EUR includes existing shareholders such as Ananda ...
CAP-1002 Cell Therapy Programs Pivotal Phase 3, HOPE-3 Trial Initiation Underway- Entered Exclusive Partnership with Nippon Shinyaku for Commercialization and Distribution of CAP-1002 for Duchenne Muscular Dystrophy in United States- Capricor to Receive Upfront Payment of $30 Million with Additional Milestone Payments of up to $705 Million- Phase 2 INSPIRE Top-Line Data Expected by End of ...
Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today the publication of a large real-world clinical utility study in Urology Practice, a peer-reviewed journal of the American Urological Association. The study, led by Dr. Eric Klein, Emeritus Professor and Chair of the Glickman Urological ...
AcuPebble SA100 is clinically equivalent to cardiorespiratory polygraphy for the automated diagnosis of obstructive sleep apnea (OSA) at home, a paper published in the BMJ Open has revealed. A powered clinical trial conducted by the Royal Free Hospital in London demonstrated both the accuracy and usability of the small device, which has the potential to open more efficient patient pathways for ...
The Biomedical Bioinformatics Platform belongs to CD Genomics and has a good reputation for assisting researchers with data analysis challenges, including NGS data processing, analysis, interpretation, and general genomic data analysis, as well as data mining, statistical modeling, data integration, information science, database construction, and management. Recently, the company announced the ...
AcuPebble SA100, a small wearable device that enables automated, remote home testing to detect obstructive sleep apnoea (OSA) in adults, has obtained FDA 510(k) clearance as a Class II medical device in the USA. The device, which received a CE Mark as a Class IIa medical device in 2020, was developed and is commercialised by UK-based medical device company Acurable and builds on more than ten ...
Healx has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for the Phase 2a clinical study of the compound HLX-0201 for Fragile X syndrome. The clinical study will attempt to find at least one novel and effective combination therapy for Fragile X syndrome - the world’s leading inherited cause of autism and learning difficulties which affects ...
HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of potential lead product candidates for the treatment of gout under its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP). This milestone marks the fourth payment that HemoShear has earned, following previous payments for the identification and ...
Cleveland Diagnostics, Inc., a commercial stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that Eric Klein, MD, Chairman of the Glickman Urological & Kidney Institute at Cleveland Clinic, delivered two presentations at the annual meeting of the American Urological Association regarding the company’s prostate ...